title: Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.
abstract: BACKGROUND
  There is limited evidence to support the efficacy of current pharmaceutical agents in reducing the risk of hip fracture in older postmenopausal women with established osteoporosis.
  
  
  OBJECTIVE
  To clarify the efficacy of risedronate in reducing the risk of hip fracture in elderly postmenopausal women aged > or = 70 years with established osteoporosis, i.e., those with bone mineral density-defined osteoporosis and a prevalent vertebral fracture.
  
  
  METHODS
  Post hoc analysis of the Hip Intervention Program (HIP) study, a randomized controlled trial comparing risedronate with placebo for reducing the risk of hip fracture in elderly women. Women aged 70 to 100 years with established osteoporosis (baseline femoral neck T-score < or = -2.5 and > or =1 prior vertebral fracture) were included. The main outcome measure was 3-year hip fracture incidence in the risedronate and placebo groups.
  
  
  RESULTS
  A total of 1656 women met the inclusion criteria. After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32-0.91; P = 0.019).
  
  
  CONCLUSIONS
  Risedronate significantly reduced the risk of hip fracture in women aged up to 100 years with established osteoporosis.
authors: Nottingham University Hospitals NHS Trust, Nottingham, UK. tahir.masud@nuh.nhs.uk
authors: Tahir
authors: T
authors: Masud
authors: Michael
authors: M
authors: McClung
authors: Piet
authors: P
authors: Geusens
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006620:Hip Fractures / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D000068296:Risedronic Acid; D040242:Risk Reduction Behavior; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid